Singapore’s Healthway Medical Group is acquiring Bridgepoint Health, while China’s CATL has invested in New Zealand’s CarbonScape.
CATL invests in CarbonScape to scale bio-based graphite for EV batteries
China’s battery giant CATL has made a strategic investment in New Zealand-based CarbonScape to help commercialise bio-based graphite for electric vehicle batteries, according to a company announcement.
The partnership will combine CarbonScape’s technology, which converts forestry by-products into battery-grade graphite, with CATL’s expertise in manufacturing, industrial scale-up, and commercialization. Financial terms of the investment were not disclosed.
The transaction gives CATL board representation at CarbonScape and positions the Chinese company as a key industrialisation partner as the startup advances toward commercial production by the end of the decade. Hong Kong-based Lochpine Capital also joined the investment as a strategic shareholder.
The companies said they will validate CarbonScape’s technology at demonstration scale using CATL facilities before preparing for full-scale commercial plants.
CarbonScape, backed by CATL, Stora Enso, and Amperex Technology Limited, operates a pilot plant in New Zealand and is targeting commercial deployment in Europe and other markets.
Healthway to acquire Bridgepoint Health
Singapore-based Healt
The strategic expansion will add 16 clinics in Singapore to Healthway’s primary care footprint, as well as a team of 75 healthcare professionals, strengthening clinical collaboration, knowledge sharing and operational excellence across the company’s platform.
Healthway is currently operating more than 130 clinics and medical centres.
Together, the enlarged group is expected to serve more than 1.3 million patient visits annually, the firm said in a statement.
Healthway is majority-owned by OUE Healthcare following a delisting transaction in 2023. Private equity firm Gateway Partners, which invested in Healthway in 2017, still holds its shares in the company.
